Thalidomide Treatment Reduces Tumor Necrosis Factor α Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis

Table 4 Proliferative response of PBMC to PPD and BCG

	Lymphocyte Proliferation—counts per minute (stimulation index)
	Thalidomide		Placebo
	HIV⁺ CPM (SI)	HIV⁻ CPM (SI)	HIV⁺/⁻ CPM (SI)
Controls:
pre	704 ± 337	1239 ± 1028	1037 ± 524
mid	2264 ± 4694	2620 ± 2949	1158 ± 664
post	1487 ± 1694	1140 ± 664	1632 ± 1376
PPD:
pre	38253 ± 38987	57926 ± 41427	51878 ± 33764
	(60 ± 64)	(64 ± 46)	(63 ± 50)
mid	49341 ± 46031	44717 ± 23963	60007 ± 28475
	(52 ± 56)	(34 ± 31)	(80 ± 75)
post	44077 ± 43822	53078 ± 31411	52682 ± 43678
	(56 ± 61)	(59 ± 44)	(63 ± 52)
BCG:
pre	32879 ± 36725	22096 ± 28567	26777 ± 18977
	(42 ± 37)	(28 ± 36)	(32 ± 26)
mid	44767 ± 54076	23788 ± 17519	34200 ± 29931
	(42 ± 58)	(23 ± 32)	(42 ± 53)
post	40172 ± 42663	23259 ± 17060	27891 ± 32902
	(43 ± 50)	(26 ± 19)	(33 ± 36)

Results are means ± one standard deviation (SD) of counts per minute (stimulation indexes) of proliferative responses to antigen stimulation of PBMC tested before (pre), during (mid), and 5 days after (post) treatment with thalidomide or placebo (see Table 1). No significant changes were observed.

ISSN: 1528-3658